eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.
eGenesis is utilizes breakthrough gene editing technologies for the development of safe and effective human-compatible organs to address the global organ shortage.
eGenesis was founded in 2015 by Luhan Yang and George Church. The company is headquartered in Cambridge, Massachusetts, with an office in New York.
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells.
eGenesis is uniquely positioned to reinvigorate the field of xenotransplantation by addressing both the key virology and immunology hurdles that have impeded its advancement to date and provide commercially-viable products to save and enhance the lives of patients in need.
eGenesis is advancing an initial product toward the clinic for kidney transplant, with the longer-term potential of addressing a broader organ recipient population and expanding the applicability of xenotransplantation into other areas such as cell therapy. Learn more at egenesisbio.com.
eGenesis is backed by Fresenius Medical Care Ventures (FMCV), Leaps by Bayer, Wellington Partners, ARCH Venture Partners, Biomatics Capital, Alta Partners, Khosla Ventures and others. The company raised $100M from a "Series B" financing on Nov 07, 2019. This new round brings eGenesis' total funding to $138M to date.